Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03974022 · ClinicalTrials.gov registry record · Phase 1
Assessing an Oral EGFR Inhibitor, Sunvozertinib in Patients Who Have Advanced Non-small Cell Lung Cancer With EGFR or HER2 Mutation (WU-KONG1)
A Phase 1 study of Non-Small Cell Lung Cancer, sponsored by Dizal Pharmaceuticals.
- Active
- Registry status
- Phase 1
- Development phase
- 315
- Enrollment target
- 20
- Study locations
NCT03974022 is a Phase 1 study of Non-Small Cell Lung Cancer that is active but no longer recruiting, run by Dizal Pharmaceuticals. The registered enrollment target is 315 participants, below the 658-participant average among 449 other Non-Small Cell Lung Cancer trials with a reported enrollment target (52% lower). The trial reports 20 study locations across 9 states.
The verdict
NCT03974022, a Phase 1 study of Non-Small Cell Lung Cancer, is active but no longer recruiting, sponsored by Dizal Pharmaceuticals.
- ACTIVE NOT RECRUITING
- Registry status
- Phase 1
- Development phase
- 315 participants
- Enrollment target
- 20
- Study locations
Study Summary
This study will treat patients with advanced NSCLC with EGFR or HER2 mutation who have progressed following prior therapy. This is the first time this drug is tested in patients, and so it will help to understand what type of side effects may occur with the drug treatment. It will also measure the levels of drug in the body and preliminarily assess its anti-cancer activity as monotherapy.
Conditions Studied
Interventions
- DRUG Sunvozertinib
Study Locations (20)
Other
- Fundacion Respirar - Consultorios Medicos Dr. Doreski - Cabildo
- CEMIC Centro de Educación Médica e Investigaciones Clínicas - Hospital Universitario sede Saavedra - Ciudad Autónoma Buenos Aires
- Centro Medico Austral OMI - Ciudad Autónoma Buenos Aires
- Diabaid - Ciudad Autónoma Buenos Aires
- Fundacion CENIT Para La Investigacion en Neurociencias - Ciudad Autónoma Buenos Aires
- Instituto Argentino de Diagnositco y Tratamiento S.A. - Ciudad Autónoma Buenos Aires
- Instituto Medico de la Fundacion de Estudios Clínicos - Ciudad Autónoma Buenos Aires
- Centro de Investigación Pergamino SA - Pergamino
California
- University of California, San Diego (UCSD) - Moores Cancer Center - La Jolla
- University of California Irvine Medical Center (UCIMC) - Chao Family Comprehensive Cancer Center - Orange
- Innovative Clinical Research Institute, LLC - Whittier
New York
- Northwell Health - Centers for Advanced Medicine - New Hyde Park
- Laura and Isaac Perlmutter Cancer Center - New York
- Icahn School of Medicine at Mount Sinai - New York
Colorado
- University of Colorado Hospital - Anschutz Cancer Pavilion - Aurora
Florida
- H. Lee Moffitt Cancer Center & Research Institute - Tampa
Massachusetts
- Dana-Farber Cancer Institute - Boston
Michigan
- Michigan Center of Medical Research - Farmington Hills
Ohio
- The Ohio State University Comprehensive Cancer Center - Columbus
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 315 participants |
| Start Date | 2019-07-09 |
| Est. Completion | 2026-12 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT03974022
The ClinicalTrials.gov registry entry for NCT03974022 describes a study currently listed as active not recruiting, categorized as Phase 1. The registered enrollment target is 315 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 658-participant average among 449 other Non-Small Cell Lung Cancer trials with a reported enrollment target (52% lower). The listed sponsor is Dizal Pharmaceuticals, which has 15 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with Non-Small Cell Lung Cancer appearing as the primary indexed condition, and to 1 intervention - of which Sunvozertinib is the first listed.
NCT03974022 reports 20 study locations spanning 9 distinct geographic areas - top geographies include Other, California, New York.
Frequently Asked Questions
What is clinical trial NCT03974022 about?
NCT03974022 is a clinical study titled "Assessing an Oral EGFR Inhibitor, Sunvozertinib in Patients Who Have Advanced Non-small Cell Lung Cancer With EGFR or HER2 Mutation (WU-KONG1)". This study will treat patients with advanced NSCLC with EGFR or HER2 mutation who have progressed following prior therapy. This is the first time this drug is tested in patients, and so it will help to understand what type of side effects may occur with the drug treatment. It will also measure the l...
What is the current status of trial NCT03974022?
This trial is currently active not recruiting. It is a Phase 1 study. The enrollment target is 315 participants. The study started on 2019-07-09. Estimated completion is 2026-12.
What conditions does trial NCT03974022 study?
This clinical trial studies the following conditions: Non-Small Cell Lung Cancer.
What interventions are being tested in trial NCT03974022?
The interventions under investigation include: Sunvozertinib (DRUG).
Who is sponsoring clinical trial NCT03974022?
This trial is sponsored by Dizal Pharmaceuticals, which has 15 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT03974022 being conducted?
This trial has 20 study locations across California, Colorado, Florida, Massachusetts, Michigan. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Non-Small Cell Lung Cancer
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
A Study to Evaluate Safety, Efficacy, and Pharmacokinetics in Participants With Advanced Solid Tumors
RECRUITING · Phase 1
-
A Study to Learn About the Study Medicine Called PF-08634404 in Combination With Different Anticancer Agents in Advanced Cancers
RECRUITING · Phase 1
-
Neoadjuvant Dupilumab and Cemiplimab in Patients With Early-stage Resectable NSCLC
RECRUITING · Phase 1
-
A Study Investigating BG-60366 in Adults With Epidermal Growth Factor Receptor (EGFR)-Mutant Non-Small Cell Lung Cancer
RECRUITING · Phase 1
-
Clinical Trial Evaluating the Safety, Tolerability and Preliminary Efficacy of BNT116 Alone and in Combinations in Patients With Advanced Non-small Cell Lung Cancer
RECRUITING · Phase 1
-
A Study of a Selective ERBB2 Inhibitor (CGT4255), in Patients With Advanced Solid Tumors
RECRUITING · Phase 1
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.